<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00133003</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE No. A00500</org_study_id>
    <nct_id>NCT00133003</nct_id>
  </id_info>
  <brief_title>Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2)</brief_title>
  <official_title>Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of the Glycoprotein IIb/IIIa Inhibition With Abciximab in Patients With ACS Undergoing Coronary Stenting After Pretreatment With a High Loading Dose of Clopidogrel (ISAR-REACT-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether there is any additional benefit from
      abciximab administration during percutaneous coronary intervention in patients presenting
      with acute coronary syndromes after pre-treatment with 600mg of clopidogrel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although percutaneous coronary interventions (PCIs) are an established therapeutic approach
      in patients presenting with acute coronary syndrome (ACS), it is still unclear which the best
      antithrombotic therapy to be applied periprocedurally is. The EPISTENT trial has shown that
      adding abciximab (a glycoprotein [GP] IIb/IIIa receptor inhibitor) to the therapy with
      ticlopidine plus aspirin significantly reduces the incidence of ischemic complications
      (death, myocardial infarction or reinterventions) after coronary stent implantation.
      Ticlopidine also reduces procedural complications but has a delayed onset of action after
      coronary stenting and has been replaced by clopidogrel, which provides similar efficacy and
      is associated with fewer side effects. Experimental studies have shown that a 600 mg loading
      dose of clopidogrel is safe and acts rapidly leading to a maximal inhibition of platelet
      aggregation within 2 hours after administration. In the ISAR-REACT trial, a 600 mg loading
      dose of clopidogrel was well tolerated, and associated with such a low frequency of early
      complications that the use of abciximab offered no clinically measurable benefit at 30 days.
      Although patients with ACS have frequently been treated with a &quot;cooling-off&quot; strategy for &gt;48
      hours before undergoing PCI, the ISAR-COOL trial demonstrated that patients undergoing PCI
      within 6-12 hours of presentation with an ACS actually suffer a lower rate of ischemic
      complications than those for whom an invasive approach is delayed. However, patients with ACS
      represent a higher risk subset and may need a more potent antithrombotic regimen
      periprocedurally. Therefore, the results of ISAR REACT, which was performed in low and
      intermediate risk patients, should not be generalized to high risk patients.

      Comparison:

      All patients with non-ST-segment elevation acute coronary syndromes who will undergo coronary
      angiography willing to participate in the trial will receive a loading dose of 600 mg
      clopidogrel at least 2 hours prior to the procedure. Eligible patients who do not meet the
      exclusion criteria in whom angiography reveals that PCI is planned will be randomized to
      receive either abciximab plus low-dose heparin, 70 units/kg, or high dose heparin (140
      units/kg) plus placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite rate of death, myocardial infarction, and urgent target vessel revascularization within 30 days</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major and minor bleeding complications in-hospital</measure>
    <time_frame>in hospital</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death or myocardial infarction by 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization by 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2022</enrollment>
  <condition>Coronary Disease</condition>
  <condition>Angina, Unstable</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abciximab</intervention_name>
    <description>0.25 mg/kg of body weight bolus, followed by a 0.125-microg/kg per minute [maximum, 10 microg/min] infusion for 12 hours, plus heparin, 70 U/kg of body weight</description>
    <arm_group_label>1</arm_group_label>
    <other_name>ReoPro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo consist of placebo bolus and infusion of 12 hours (NaCl 0.9%), plus heparin bolus, 140 U/kg of body weight</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with acute coronary syndromes

          -  Pretreatment (2 hours) with high loading dose (600 mg) clopidogrel

          -  Significant angiographic lesions amenable to and requiring a PCI

          -  Written informed consent

        Exclusion Criteria:

          -  ST-segment elevation acute myocardial infarction within 48 hours from symptom onset

          -  Hemodynamic instability

          -  Pericarditis

          -  Malignancies with life expectancy less than one year

          -  Increased risk of bleeding

          -  Oral anticoagulation therapy with coumarin derivative within 7 days

          -  Recent use of GPIIb/IIIa inhibitors within 14 days

          -  Severe uncontrolled hypertension &gt;180 mmHg unresponsive to therapy

          -  Relevant hematologic deviations: hemoglobin &lt; 100g/L or hematocrit &lt; 34%; platelet
             count &lt; 100 x 10^9/L or platelet count &gt; 600 x 10^9/L.

          -  Known allergy to the study medication

          -  Pregnancy (present or suspected)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Schomig, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adnan Kastrati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter B Berger, MD</last_name>
    <role>Study Director</role>
    <affiliation>Duke Clinical Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Dante Pazzanese de Cardiologia</name>
      <address>
        <city>São Paulo</city>
        <zip>500-04012180</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz-Zentrum</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Medizinische Klinik, Klinikum rechts der Isar</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Topol EJ, Mark DB, Lincoff AM, Cohen E, Burton J, Kleiman N, Talley D, Sapp S, Booth J, Cabot CF, Anderson KM, Califf RM. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet. 1999 Dec 11;354(9195):2019-24. Erratum in: Lancet 2000 Mar 25;355(9209):1104.</citation>
    <PMID>10636365</PMID>
  </reference>
  <reference>
    <citation>Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Bertrand M, Neumann FJ, Stone GW, DiBattiste PM, Demopoulos L; TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001 Jun 21;344(25):1888-94.</citation>
    <PMID>11419425</PMID>
  </reference>
  <reference>
    <citation>Neumann FJ, Kastrati A, Pogatsa-Murray G, Mehilli J, Bollwein H, Bestehorn HP, Schmitt C, Seyfarth M, Dirschinger J, Schömig A. Evaluation of prolonged antithrombotic pretreatment (&quot;cooling-off&quot; strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. JAMA. 2003 Sep 24;290(12):1593-9.</citation>
    <PMID>14506118</PMID>
  </reference>
  <reference>
    <citation>Müller I, Seyfarth M, Rüdiger S, Wolf B, Pogatsa-Murray G, Schömig A, Gawaz M. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart. 2001 Jan;85(1):92-3.</citation>
    <PMID>11119474</PMID>
  </reference>
  <reference>
    <citation>Pache J, Kastrati A, Mehilli J, Gawaz M, Neumann FJ, Seyfarth M, Hall D, Braun S, Dirschinger J, Schömig A. Clopidogrel therapy in patients undergoing coronary stenting: value of a high-loading-dose regimen. Catheter Cardiovasc Interv. 2002 Apr;55(4):436-41.</citation>
    <PMID>11948888</PMID>
  </reference>
  <reference>
    <citation>Kastrati A, Mehilli J, Schühlen H, Dirschinger J, Dotzer F, ten Berg JM, Neumann FJ, Bollwein H, Volmer C, Gawaz M, Berger PB, Schömig A; Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med. 2004 Jan 15;350(3):232-8.</citation>
    <PMID>14724302</PMID>
  </reference>
  <results_reference>
    <citation>Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, Schühlen H, Dirschinger J, Berger PB, Schömig A; Intracoronary Stenting and Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA. 2006 Apr 5;295(13):1531-8. Epub 2006 Mar 13.</citation>
    <PMID>16533938</PMID>
  </results_reference>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2005</study_first_submitted>
  <study_first_submitted_qc>August 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2005</study_first_posted>
  <last_update_submitted>April 12, 2008</last_update_submitted>
  <last_update_submitted_qc>April 12, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2008</last_update_posted>
  <responsible_party>
    <name_title>Deutsches Herzzentrum Muenchen</name_title>
    <organization>Deutsches Herzzentrum Muenchen</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Abciximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin Fab Fragments</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

